Terms: = Gastric cancer AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1 AND Clinical Outcome
2 results:
1. A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer.
Liu X; Guo W; Zhang W; Yin J; Zhang J; Zhu X; Liu T; Chen Z; Wang B; Chang J; Lv F; Hong X; Wang H; Wang J; Zhao X; Wu X; Li J
BMC Cancer; 2017 Mar; 17(1):188. PubMed ID: 28288572
[TBL] [Abstract] [Full Text] [Related]
2. Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Luber B; Deplazes J; Keller G; Walch A; Rauser S; Eichmann M; Langer R; Höfler H; Hegewisch-Becker S; Folprecht G; Wöll E; Decker T; Endlicher E; Lorenzen S; Fend F; Peschel C; Lordick F
BMC Cancer; 2011 Dec; 11():509. PubMed ID: 22152101
[TBL] [Abstract] [Full Text] [Related]
